ArticleFrontiers in neurology2025
B-cell immune repertoire analysis of autoimmune neurological syndromes with anti-GAD65 antibodies.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From gastric to neuroprotection: pantoprazole mitigates epilepsy via TrkB/BDNF and KCC2 modulation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Unveiling the Clinical Impact of Lower Limb Robotic Devices in Neurorehabilitation: An Umbrella Review.Annals of biomedical engineering · 2026Review
- Retinal microvascular changes in patients with transient ischemic attack and minor ischemic stroke: multimodal insights from the REMARK-TIA study.Journal of neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune neurological syndromes (AINS) associated with anti-GAD65 antibodies encompass a spectrum of disorders, including limbic encephalitis (LE), stiff-person syndrome (SPS), and cerebellar ataxia (CA). Despite the universal presence of anti-GAD65 antibodies across these syndromes, patients exhibit remarkable clinical phenotypic diversity. Exploring the overall B-cell receptor (BCR) profile of patients with anti-GAD65 AINS may provide clues to the molecular pathological mechanisms underlying this phenotypic diversity. Methods: We performed high-throughput B-cell receptor (BCR) heavy-chain sequencing (Illumina NovaSeq 6000) on peripheral blood samples from 9 anti-GAD65 AINS patients (7 LE, 1 SPS, 1 CA/SPS overlapping) and 11 healthy controls (HC). Analysis encompasses clonotype profiling, somatic hypermutation (SHM) rates, CDR3 physicochemical characterization, repertoire diversity, and machine learning-based VDJ feature identification. Results: Anti-GAD65 LE showed significantly reduced repertoire diversity versus HC (Chao1: Conclusions: BCR repertoire heterogeneity across anti-GAD65 AINS subtypes illuminates the immunological underpinnings of phenotypic diversity. The identified VDJ signatures and common clonotypes represent candidate biomarkers for precise diagnosis and rational targets for BCR-lineage-directed immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.